EC
BBIO icon

Elequin Capital’s BridgeBio Pharma BBIO Stock Holding History

Elequin Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-323
Closed -$24K – 723
2026
Q1 		$24K Sell
323
-357
-53% -$25.9K ﹤0.01% 241
2025
Q4 		$52K Buy
+680
New +$44.6K ﹤0.01% 141
2025
Q1 		– Sell
-303
Closed -$8.31K – 351
2024
Q4 		$8.31K Buy
303
+15
+5% +$388 ﹤0.01% 368
2024
Q3 		$7.33K Sell
288
-26
-8% -$683 ﹤0.01% 263
2024
Q2 		$7.95K Sell
314
-8
-2% -$219 ﹤0.01% 150
2024
Q1 		$9.96K Buy
+322
New +$11K ﹤0.01% 108
2023
Q3 		– Sell
-678
Closed -$11.7K – 415
2023
Q2 		$11.7K Buy
+678
New +$10.2K 0.01% 282
2022
Q4 		– Sell
-549
Closed -$5K – 630
2022
Q3 		$5K Sell
549
-426
-44% -$4.43K ﹤0.01% 320
2022
Q2 		$9K Buy
975
+92
+10% +$769 ﹤0.01% 244
2022
Q1 		$9K Buy
+883
New +$9.06K ﹤0.01% 168

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Elequin Capital's BBIO Position: Q2 2026 in Review

Elequin Capital sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 323 shares — an estimated $24K sold.

Elequin Capital first reported a position in BBIO in Q1 2022 and held it in 10 quarters. The position peaked at $52K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Elequin Capital reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Elequin Capital sold 323 BridgeBio Pharma shares in Q2 2026, an estimated $24K.
  • Elequin Capital first reported a position in BridgeBio Pharma in Q1 2022 and held it in 10 quarters.
  • Elequin Capital's BridgeBio Pharma position peaked at $52K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.